If you catch Tollovid daily on sale, it's $150 for 2

New Post Public Reply Private Reply Replies (1) Message Board
redspeed freegriff #29583
593
If you catch Tollovid daily on sale, it's $150 for 2 bottles

If you take one a day that's $1.25 a day. If you take two, $2.50

About the price of a Freshly Brewed Coffee - Venti size whatever that is and far less than a Pumpkin Spice Latte Venti

Is Starbucks a products for the masses? idk, never been there except at an airport to get an overpriced croissant.

Tollovid is less then a Big Mac but are those for the masses either?

Tollovid might be more a less prices you find at your local Cannabis. Last time I drove by there was masses waiting in line to buy something.

Point is, people make choices based on what is important to them. Sacrafices. Tradeoffs.

I do agree there are a lot of people that wish they even had a chance at a choice of a Big Mac or Starbucks, but there are masses that do as well.

If the government wants to step in and help, fantastic. If insurance companies what to help, fantastic. They might figure out at some point a bottle of Tollovid Max is far cheaper than a hospital stay, but we are a ways away from that sinking in.

My copay for an ER visit is $250. Probably on it's way up. More than a bottle of Tollovid Max onsale with the BOGO2H. No brainer for me because if I am out of work, I will lose way more than $250.

If one dug into SOC, they would know what is included. If Gerald wasn't hand holding JP and people that invested way over their heads on twitter, maybe someone would have thought to ask him or did a 2 second google search?

Even if Gerald spends all his waking hours telling shareholders every last detail so they won't be concerned or upset, it's just more ammo for JP and the bedwetting crew to use.

https://www.idsociety.org/practice-guideline/...anagement/

Click on the second blue bar. Second column to the right to see what you could get in the hospital besides a meal and clean sheets.

Does it matter that people were getting Remsdesivir, oxygen, etc? Where do you draw the line in trial? Even better yet, who is going to try something new, while they are dying and they have been lead to believe remsdesivir may save their life?

Reminds me of when Gerald said on Thursday, if Tollovir gets and EUA, who the hell can they find to take a placebo? I think it's going to get an EUA. It would be immoral to watch people die without trying.

"Hey, just checked on Billy. He's not going to make it. Oh well, wish we could have tried Tollovid, but it's not EUA."

Is Gerald going to review the phase 2/3 trial design with me? No.

Do I expect him to. No.

Do I trust they know what they are doing. Yes or I wouldn't be invested.

Wasn't the formulation change in middle of a trial? Did they stop for months and start another one or was it part of the same trial? I can look on the trial websites. I thought what happens within the trials in confidential?

Doesn't bother me at all. I look at it as a blessing. I'd have to go back and look to see if it was actually strength that they were getting wasn't strong enough, so they cranked it up. Wouldn't be too far different than someone was getting x pills and took y pills.

What I learned over the years if I told my business customers everything they think they wanted to know, they'd jump on the window with worry. Anyway, I bought at the high and low of the week. At one point, I confess...
I did open the window. As the car was getting pretty hot.

Not concerned at all or disappointed in the progress and transparency, but that is just me. Everyone's expectations and risk tolerance is different for sure.

I agree about your last part. Seems like there will always be manipulators. Uplisting isn't the cure either. But if Todos continues on focusing and executing, that can solve a lot of it.












Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Indiana Michigan Power Expands Energy Reach with Acquisition

Updated Category News Views 253

I&M Plans for Sustainable Energy Future Indiana Michigan Power (I&M), part of American Electric Power (NASDAQ: AEP), is making significant strides towards bolstering its energy infrastructure. Recently receiving approval from the Indiana Utility Regulatory Commission (IURC) to acquire the Oregon Clean Energy Center, I&M is focused on delivering reliable and affordable...

Continue Reading
Enhance Your Breathing: Discover Naväge's New SaltPods

Updated Category News Views 163

Breathe Easier Every Day with Naväge® SaltPods The new SaltPods from Naväge feature essential oils combined with saline solution to amplify the nasal rinsing experience and support better breathing throughout the day. Introducing Innovative Nasal Rinsing Solutions Naväge®, a trusted leader in drug-free nasal care, has introduced an exciting addition to wellness...

Continue Reading
O2Gold Increases Financing While Finalizing Quebec Acquisition

Updated Category News Views 185

O2Gold Updates on Major Acquisition and Financing Strategy O2Gold Inc. (NASDAQ: OTGO) is excited to share recent developments regarding its acquisition of a gold mining exploration property in Quebec. This deal involves purchasing all outstanding shares of Quebec Aur Ltd., a move aligned with O2Gold's vision of expanding its mining portfolio. Details on the Acquisition...

Continue Reading
SKYX Technologies Secures $4 Million Preferred Stock Funding

Updated Category News Views 254

SKYX Technologies Secures Significant Funding for Growth MIAMI — SKYX (NASDAQ: SKYX), a leader in smart home platform technologies, has made headlines by securing approximately $4 million in preferred stock funding. This investment comes from strategic investors who purchased shares at a value of $2.00 each. This move is part of a larger financing round, bringing the...

Continue Reading
Coinbase CEO Armstrong's Recent Share Sale Shakes Market

Updated Category News Views 145

Coinbase CEO's Share Sale Influences Market Dynamics Coinbase Global Inc (NASDAQ: COIN) recently experienced a notable decline from its three-year high. This shift occurred following the announcement that CEO Brian Armstrong sold approximately $300 million worth of shares, marking the second major share sale in November. Investors closely follow such transactions, as they...

Continue Reading